8-K: Intelligent Bio Solutions Details 2024 Growth, Anticipates U.S. Market Entry in 2025

Intelligent Bio Solutions recapped its 2024 growth, highlighting a 148% year-over-year revenue increase and its plans for U.S. market expansion in 2025 following FDA 510(k) submission.

Summary

• Intelligent Bio Solutions (INBS) released a shareholder letter detailing the company's progress in 2024 and its strategy for 2025.
• The company achieved significant revenue growth in fiscal 2024, with a 148% year-over-year increase.
• INBS submitted a 510(k) pre-market notification to the FDA in December 2024, aiming for U.S. market entry in 2025.
• The company's preliminary results for the second quarter ended December 31, 2024, show expected revenue of approximately $0.61 million and $1.48 million for the six months.
• Gross profit for the six months ended December 31, 2024, is anticipated to increase by 32.6% to $0.57 million, with the gross profit margin growing to 38.5% from 27.7%.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the company's revenue growth, progress towards FDA approval, and positive preliminary financial results. However, it's tempered by the inherent risks and uncertainties associated with FDA approval and market entry.

Positives

• The company experienced substantial revenue growth of 148% year-over-year in fiscal 2024.
• Successful Pharmacokinetic and Method Comparison studies support the FDA 510(k) submission.
• The Method Comparison Study demonstrated approximately 94% accuracy for the company's Drug Screening System.
• Preliminary Q2 FY2025 results show an increase in gross profit and gross profit margin.
• The company has a diversified customer base across multiple industries and countries.
• Strategic focus on higher-margin cartridge sales is driving gross profit margin expansion.

Negatives

• The company is still in the process of seeking FDA approval for its product in the U.S.
• Rising drug positivity rates and test tampering present ongoing challenges in the industry.

Risks

• There is no guarantee that the FDA will approve the company's 510(k) submission.
• The company faces competition from established players in the drug screening market.
• Changes in regulations or market conditions could impact the company's growth prospects.
• The company may need to raise additional capital to fund its expansion plans.
• Drug test tampering rates are increasing, which could impact the perceived need for the company's product if not addressed effectively.

Future Outlook

The company plans to enter the U.S. market in 2025, pending FDA approval. They anticipate growing demand for faster, non-invasive testing solutions and are focused on expanding cartridge sales as a primary source of recurring revenue.

Management Comments

• 2024 was a pivotal year for the Company, in which we met several critical milestones.
• We remain on track to enter this exciting market [U.S.] in 2025.
• We are excited to build upon this success and execute on our U.S. expansion plans.
• Our strategic focus on higher-margin cartridge sales has driven a significant 11-point expansion in gross profit margin.

Industry Context

The global drug screening market is projected to reach almost $15 billion in the next six years. Rising substance abuse, stricter regulations, and increased focus on workplace safety are driving demand for drug testing solutions. Increased rates of drug test tampering are also a concern.

Comparison to Industry Standards

• Quest Diagnostics' 2024 Drug Testing Index Report highlighted a 4.7% increase in marijuana positivity rates in the general U.S. workforce over the past year and a 45% increase over the past five years.
• Cocaine positivity in the general U.S. workforce increased by 9.1% in 2023, according to Quest Diagnostics.
• Quest Diagnostics also reported a six-fold increase in drug test tampering in the U.S. workforce in 2023 compared to 2022.
• Grand View Research states the U.S. accounted for approximately 28% of the global drug screening market in 2023.

Stakeholder Impact

• Shareholders: Potential for increased value if the company successfully enters the U.S. market and continues to grow.
• Employees: Potential for job creation and growth opportunities as the company expands.
• Customers: Access to a new, non-invasive drug testing solution.
• Suppliers: No impact mentioned.
• Creditors: No impact mentioned.

Next Steps

• Await FDA decision on the 510(k) pre-market notification.
• Prepare for U.S. market entry.
• Continue to focus on driving cartridge sales.

Key Dates